Detalhe da pesquisa
1.
Treatment with lenalidomide does not appear to increase the risk of progression in lower risk myelodysplastic syndromes with 5q deletion. A comparative analysis by the Groupe Francophone des Myelodysplasies.
Haematologica
; 97(2): 213-8, 2012 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-21993675